FY2028 EPS Estimates for argenex Increased by HC Wainwright

argenex SE (NASDAQ:ARGX) – Research analysts at HC Wainwright increased their FY2028 earnings per share estimates for shares of argenex in a research report issued to clients and investors on Friday, October 31st. HC Wainwright analyst D. Tsao now expects that the company will post earnings of $47.85 per share for the year, up from their previous forecast of $46.14. HC Wainwright has a “Buy” rating and a $915.00 price target on the stock. The consensus estimate for argenex’s current full-year earnings is $3.13 per share. HC Wainwright also issued estimates for argenex’s FY2029 earnings at $55.93 EPS.

ARGX has been the topic of several other research reports. Wells Fargo & Company boosted their price target on argenex from $741.00 to $756.00 and gave the company an “overweight” rating in a research note on Thursday, July 31st. Zacks Research lowered argenex from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 21st. Bank of America boosted their price objective on argenex from $880.00 to $887.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Wedbush boosted their price objective on argenex from $800.00 to $880.00 and gave the stock an “outperform” rating in a research note on Monday, October 13th. Finally, Morgan Stanley boosted their price objective on argenex from $766.00 to $1,040.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 1st. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $851.70.

argenex Price Performance

Shares of ARGX stock opened at $826.28 on Monday. The stock’s fifty day simple moving average is $772.12 and its 200 day simple moving average is $656.46. The firm has a market cap of $50.87 billion, a price-to-earnings ratio of 35.48, a P/E/G ratio of 0.94 and a beta of 0.45. argenex has a one year low of $510.05 and a one year high of $855.46.

Hedge Funds Weigh In On argenex

Several large investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its stake in shares of argenex by 6.8% during the third quarter. GAMMA Investing LLC now owns 251 shares of the company’s stock valued at $185,000 after acquiring an additional 16 shares during the period. Cromwell Holdings LLC lifted its stake in shares of argenex by 10.0% during the third quarter. Cromwell Holdings LLC now owns 187 shares of the company’s stock valued at $138,000 after acquiring an additional 17 shares during the period. Greenleaf Trust lifted its stake in shares of argenex by 3.5% during the first quarter. Greenleaf Trust now owns 624 shares of the company’s stock valued at $369,000 after acquiring an additional 21 shares during the period. Main Management ETF Advisors LLC lifted its stake in shares of argenex by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 1,466 shares of the company’s stock valued at $808,000 after acquiring an additional 24 shares during the period. Finally, Wilmington Savings Fund Society FSB lifted its stake in shares of argenex by 1.1% during the third quarter. Wilmington Savings Fund Society FSB now owns 2,126 shares of the company’s stock valued at $1,568,000 after acquiring an additional 24 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.